Blockade of VEGFR-1 and VEGFR-2 Enhances Paclitaxel Sensitivity in Gastric Cancer Cells

Jun-Eul Hwang, Ji-Hee Lee, Mi-Ra Park, Dae-Eun Kim, Woo-Kyun Bae, Hyun-Jeong Shim, Sang-Hee Cho, and Ik-Joo Chung

Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.

Received: February 24, 2012
Revised: April 10, 2012
Accepted: April 23, 2012
Corresponding author: Dr. Ik-Joo Chung, Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun 519-763, Korea. Tel: 82-61-379-7632, Fax: 82-61-379-7628 E-mail: ijchung@chonnam.ac.kr

The authors have no financial conflicts of interest.

© Copyright:
Yonsei University College of Medicine 2013
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Although the incidence and mortality of gastric cancer have decreased in the Western world, gastric cancer persists as a common malignancy and leading cause of cancer-related death in Asian countries.1,2 Surgery is the only curative treatment for gastric cancer. Chemotherapy achieves favorable results for resectable advanced...
and recurrent gastric cancers; however, the prognosis for these cancers is very poor.

Taxanes such as paclitaxel and docetaxel are a class of anticancer agents that bind to the β tubulin subunit of polymerized microtubules and induce hyperstabilization, which causes cell cycle arrest and apoptosis.3 Taxanes are used most commonly for the treatment of breast, lung, ovary, and gastric cancer. The taxanes paclitaxel and docetaxel exhibit similar efficacies in gastric cancer treatment.4-11

There are at least eight mammalian β tubulin isotypes, and the isotype composition in humans varies across tissues.12 Overexpression of class III β tubulin (TUBB3) has been observed in several human cancer cell lines such as prostate, ovarian, breast, and non small cell lung cancer. Cells expressing TUBB3 show resistance to docetaxel and paclitaxel.12-15 A small cohort study of advanced gastric cancer patients who were receiving preoperative docetaxel-based chemotherapy detected a correlation between expression of TUBB3 and poor response to chemotherapy.16

Hypoxia in solid tumors is associated with resistance to chemotherapy, induction of angiogenesis, and poor patient prognosis, and angiogenesis is a hallmark of human malignancies. The induction of vascular endothelial growth factor (VEGF), mediated by interacting genetic and environmental signals, is an essential component of tumor angiogenesis.17

The transcription factor hypoxia-inducible factor-1α (HIF-1α) is a primary regulator of VEGF during hypoxic conditions, and Calvani, et al.18 reported that inhibition of VEGF or the VEGF receptor-2 (VEGFR-2), abolishes VEGF-mediated induction of HIF-1α. That is, HIF-1α increases VEGF induction, and VEGF also induces HIF-1α expression. A recent report suggested that HIF-1α also mediates TUBB3 induction in hypoxia.19-21 Through these results, we postulated that blockade of VEGF in gastric cancer cells would be associated with a decrease in HIF-1α and TUBB3 expression and a concomitant increase in sensitivity to paclitaxel.

The response of gastric cancer cells to anti-VEGF antibodies is of interest because bevacizumab, a humanized monoclonal antibody against VEGF, is used currently as an anti-angiogenic treatment for metastatic colorectal cancer, non-squamous non-small cell lung cancer, and metastatic breast cancer.22-24 Recent the Avastin in Gastric Cancer trial evaluated the efficacy of adding bevacizumab to chemotherapy in the first-line treatment of advanced gastric cancer. Adding bevacizumab to chemotherapy was associated with significant increases in progression free survival and overall response rate, but not associated with significant increases in overall survival.24 To date, we had insufficient evidences for the benefit of adding bevacizumab to chemotherapy in the treatment of gastric cancer.

Placental growth factor (PIGF) was discovered shortly after VEGF. Whereas VEGF binds both VEGFR-1 and VEGFR-2, PIGF binds to VEGFR-1 but not VEGFR-2. The key role of VEGF and its receptor VEGFR-2 in tumor angiogenesis is firmly established, but the contribution of VEGFR-1 remains poorly defined.25 In the present study, we investigated the relationships between VEGF, HIF-1α, and TUBB3 in gastric cancer cells (AGS). We report that blockade of VEGFR-1 and VEGFR-2 with concomitant paclitaxel treatment increase the cell cytotoxicity of TUBB3-expressing gastric cancer cells.

### MATERIALS AND METHODS

**Drugs and reagents**

Paclitaxel (BMS Pharmaceuticals, New York, NY, USA) and bevacizumab (Roche Pharmaceuticals, Basel, Switzerland) were diluted in absolute DMSO. This solution was diluted to 0.1% DMSO on each day of experimentation. The PIGF and VEGFR-1/2 neutralizing monoclonal antibodies were purchased from research and development systems.

**Cell culture and hypoxic treatment**

The human gastric cancer cell lines, AGS, SNU, and TMK1 were used as in vitro model systems. Cells were cultured in RPMI 1640 with 10% fetal bovine serum. For normoxia, cultures were incubated at 37°C in a humidified chamber of 5% CO2. For hypoxia, cells were treated with CoCl2. Confirmatory experiments under hypoxic conditions (1% O2/5% CO2/94% N2) were performed using a Modular Incubator Chamber-101. Each hypoxia experiment was conducted under CoCl2-treated and true hypoxic conditions, and the results were equivalent.

**siRNA**

The TUBB3 siRNA duplex targeted a sequence 531 bases downstream of the TUBB3 start codon (siTUBB3: 5’-CAC GGTGTTGGAGCCCCCTAA-3’). siRNA duplex oligonucleotides were purchased from QIAGEN (Gaithersburg, MD, USA) and transfected at 100 nM using Lipofectamine RNAiMAX Reagent (Invitrogen, Carlsbad, CA, USA).
Cell proliferation assay
To estimate viability, 10^5 cells were seeded in 24-well plates, subjected to normoxia or hypoxia, and exposed to neutralizing antibodies in the culture media for 4 h. Cells were treated with bevacizumab and/or paclitaxel for 24 h. Cells were incubated for 24, 48, or 72 h, and EZ-CyTox (Daeil Lab Service, Seoul, Korea) was added to each well. After 3 h, absorbances at 420 nm were measured using a microplate reader (EL800, BioTek, Winooski, VT, USA).

Tubulin polymerization assay
Cells were treated with various concentrations of drugs for 24 h, washed twice with phosphate buffered saline, and lysed for 5 min in 100 μL hypotonic buffer [1 mM MgCl_2, 2 mM EGTA, 0.5% NP40, 20 mM Tris-HCl (pH 6.8), protease and phosphatase inhibitors]. Samples were centrifuged at 16000×g for 10 min at room temperature. Supernatants, containing soluble tubulin, were separated from pellets, containing assembled tubulin. Each fraction was separated by SDS-PAGE. Immunoblots were performed using anti-pan-α-tubulin rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Immunoblotting
Cells were lysed in Mammalian Cell Lysis Reagent (Fermentas, Waltham, MA, USA), and approximately 30 μg protein was separated in 8-10% polyacrylamide gels and transferred to polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). The following antibodies were used: anti-HIF-1α and anti-TUBB3 (Abcam PLC, Cambridge, UK), anti-tubulin (Invitrogen, Carlsbad, CA, USA), β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Statistical analysis
The Student’s t-test was used to detect significant differences among treatment groups. Statistical significance was assigned at p<0.05.

RESULTS

Induction of HIF-1α, TUBB3 and VEGF in hypoxia
The expression levels of TUBB3 and VEGF were measured during the induction of HIF-1α in hypoxic AGS. AGS exhibited well-defined hypoxic induction of HIF-1α, VEGF, and TUBB3 compared with other cell lines (SNU638, TMK1) (Fig. 1).

TUBB3 confers gastric cancer cells with resistance to paclitaxel
To assess whether TUBB3 expressions is associated with chemotherapeutic drug resistance in AGS, TUBB3 was knocked down with small interfering RNA (siTUBB3), and the effects of paclitaxel on AGS growth under normoxic and hypoxic conditions were evaluated over a 24-48 h period. AGS was strongly resistant to paclitaxel during hypoxia. Knockdown of TUBB3 decreased the resistance to paclitaxel during hypoxia, and cytotoxicity was increased (Fig. 2).

VEGFR-1 signals increase HIF-1α and TUBB3 expressions in AGS cells
After treatment with paclitaxel, cytoskeletal component were isolated from AGS cells, and tubulin polymerization was monitored. Western blots were performed using a pan-α-tubulin polyclonal antibody to probe lysates from cells that had been treated with paclitaxel or paclitaxel and beva-
cizumab under normoxic conditions or after 24 h of hypoxia. Paclitaxel activity was inhibited in hypoxia. Tubulin polymerization was decreased in hypoxia compared with normoxia and it was statistically significant ($p<0.01$). Hypoxic decrease of polymerization was lessened after treated with bevacizumab (Fig. 3A).

As previously mentioned, we postulated that blockade of VEGF in AGS would be associated with a decrease in HIF-1α and TUBB3 expression and a concomitant increase in sensitivity to paclitaxel. We treated cells with bevacizumab, anti-VEGFR-1 and anti-VEGFR-2 neutralizing antibodies to test this hypothesis. AGS cells were cultured under normoxic and hypoxic conditions for 24 h without exogenous growth factors, in the absence or presence of anti-VEGFR-1, anti-VEGFR-2, or bevacizumab with simultaneous paclitaxel treatment. HIF-1α and TUBB3 were increased in a hypoxic condition. Paclitaxel treatment decreased the hypoxia-dependent increased expression of HIF-1α and TUBB3. When paclitaxel was combined with bevacizumab or anti-VEGFR-2, expression levels of HIF-1α and TUBB3 were further decreased. The greatest decrease in HIF-1α and TUBB3 levels occurred in response to paclitaxel and anti-VEGFR-1 treatment in AGS cells (Fig. 3B). Our results using AGS cells

![Fig. 2. TUBB3 knockdown sensitizes gastric cancer cells to paclitaxel. (A)](image1)

Western blot analysis of TUBB3 in AGS cells without treatment or in the presence of si-scramble control or si-TUBB3 RNAs. Actin was used as a loading control. Band intensities were quantified by densitometry. *$p<0.05$. NS, not significant. TUBB3, class III β-tubulin; SEM, standard error of the mean.

![Fig. 3. VEGFR-1/2 contributes to tubulin polymerization. (A)](image2)

Western blots using a pan α-tubulin polyclonal antibody to probe cell lysates treated with paclitaxel with or without bevacizumab for 24 h during normoxia or hypoxia. Paclitaxel activity was inhibited in hypoxia. Tubulin polymerization was decreased in hypoxia compared with normoxia and it was statistically significant. Cells were treated with paclitaxel with/without bevacizumab at 100 nM and 100 μg/mL, respectively. Lane 1: no drug, 2: paclitaxel, 3: paclitaxel with bevacizumab. Actin was used as a loading control. Band intensities were quantified by densitometry. *$p<0.05$. Normoxia, normoxic conditions; Hypoxia, hypoxic conditions; Wild type, untreated cells; si-scramble, scrambled control siRNA; si-TUBB3, TUBB3 siRNA; 24 hr, 24 h post transfection; 48 hr, 48 h post transfection; β-actin, β-actin expression; Pellet α-tubulin, α-tubulin in the pellet fraction; Soluble α-tubulin, α-tubulin in the soluble fraction; TUBB3, TUBB3 expression; β-actin, β-actin expression. 

![Fig. 3. VEGFR-1/2 contributes to tubulin polymerization. (B)](image3)

Western blots using a pan α-tubulin polyclonal antibody to probe cell lysates treated with paclitaxel with or without bevacizumab for 24 h during normoxia or hypoxia. Paclitaxel activity was inhibited in hypoxia. Tubulin polymerization was decreased in hypoxia compared with normoxia and it was statistically significant. Cells were treated with paclitaxel with/without bevacizumab at 100 nM and 100 μg/mL, respectively. Lane 1: no drug, 2: paclitaxel, 3: paclitaxel with bevacizumab. Actin was used as a loading control. Band intensities were quantified by densitometry. *$p<0.05$. NS, not significant. TUBB3, class III β-tubulin; VEGFR, vascular endothelial growth factor receptor.

![Fig. 2.](image2)  

**A**  

Western blot analysis of TUBB3 in AGS cells without treatment or in the presence of si-scramble control or si-TUBB3 RNAs. Actin was used as a loading control. Band intensities were quantified by densitometry. *$p<0.05$. NS, not significant. TUBB3, class III β-tubulin; SEM, standard error of the mean.  

![Fig. 3.](image3)  

**A**  

Western blots using a pan α-tubulin polyclonal antibody to probe cell lysates treated with paclitaxel with or without bevacizumab for 24 h during normoxia or hypoxia. Paclitaxel activity was inhibited in hypoxia. Tubulin polymerization was decreased in hypoxia compared with normoxia and it was statistically significant. Cells were treated with paclitaxel with/without bevacizumab at 100 nM and 100 μg/mL, respectively. Lane 1: no drug, 2: paclitaxel, 3: paclitaxel with bevacizumab. Actin was used as a loading control. Band intensities were quantified by densitometry. *$p<0.05$. NS, not significant. TUBB3, class III β-tubulin; VEGFR, vascular endothelial growth factor receptor.
contrast with results using HCT116 cells, in which hypoxia-induced HIF-1α was inhibited via VEGFR-2.18

To examine VEGFR-1 function, we investigated whether the VEGFR-1 ligand, PlGF, influences the expression of HIF-1α in AGS and HCT116 cells. Cells were cultured under normoxic or hypoxic conditions in the presence of PlGF (range, 0.1-2.0 ng/mL). HIF-1α expression was increased in hypoxia and was dose dependently more increased according to the concentration of PlGF (Fig. 4A). In contrast with AGS cells, PlGF rarely influenced HIF-1α expression in HCT116 cells. AGS cells were cultured under normoxic and hypoxic conditions in the absence or presence of PlGF and anti-VEGFR-1. Expression levels of HIF-1α and TUBB3 were increased in hypoxia and were more increased in response to PlGF treatment. The increased expressions of HIF-1α and TUBB3 were suppressed when anti-VEGFR-1 antibodies were combined with PlGF treatment (Fig. 4B). We concluded that induction of HIF-1α in AGS is VEGFR-1 mediated and PlGF dependent.

**Blockade of VEGFR-1/VEGFR-2 increases sensitivity to paclitaxel in AGS cells**

AGS cells were cultured under hypoxic conditions with or without anti-VEGFR-1, anti-VEGFR-2, and bevacizumab with simultaneous paclitaxel exposure. The cell viability assay demonstrated that AGS cell cytotoxicity was increased in response to combined treatment with paclitaxel and bevacizumab compared with paclitaxel treatment alone. Cytotoxicity was increased synergistically in response to simultaneous treatment with paclitaxel, anti-VEGFR-1, and anti-VEGFR-2 (p<0.05) (Fig. 5).

**DISCUSSION**

Bevacizumab is accepted as the standard treatment for advanced metastatic colorectal cancer, but to date is not considered as the standard treatment of gastric cancer.24 VEGF can bind with the receptor tyrosine kinases, VEGFR-1 and VEGFR-2. The key roles of VEGF and its receptor VEGFR-2 in tumor angiogenesis have been established.26,27 Activation of VEGFR-2 leads to auto-phosphorylation and the activation of downstream signaling pathways, such as Raf/MEK/ERK and PI3K/Akt kinase cascades.25 In contrast, the function of VEGFR-1 remains poorly defined. VEGFR-1 has been associated with tumor growth, tumor cell ac-

---

**Fig. 4.** PlGF induces HIF-1α. (A) Nuclear HIF-1α protein expression was increased in hypoxia and was dose dependently increased according to the increased concentration of PlGF (range 0.1-2 ng/mL) in AGS. PlGF rarely influenced HIF-1α expression in HCT116 cells. Band intensities were quantified by densitometry. (B) Expression levels of HIF-1α and TUBB3 were increased in hypoxia and were more increased with PlGF treatment (1 ng/mL) in AGS cells. HIF-1α is measured from nuclear fractions, and TUBB3 is measured from total cell lysates. The observed increases in HIF-1α and TUBB3 expression levels were decreased when anti-VEGFR-1 was combined with PlGF treatment. Band intensities were quantified by densitometry. *p<0.05, †p<0.01. PlGF, placental growth factor; HIF-1α, hypoxia inducible factor-1α; TUBB3, class III β-tubulin; VEGFR, vascular endothelial growth factor receptor.
tumor growth without combined inhibition of VEGFR-2. 

However, the degree of tumor growth inhibition varies. Some studies have reported that VEGFR-2, rather than VEGFR-1, mediates VEGF-dependent induction of HIF-1α in hypoxic HCT116 colon cancer cells, suggesting that functional VEGFR-2, but not functional VEGFR-1, exists in this colon cancer cell line. Cell viability assay results demonstrated that AGS cell cytotoxicity was most pronounced when cells were treated simultaneously with paclitaxel, anti-VEGFR-1, and anti-VEGFR-2. Through these results, we suggest that AGS cells express functional VEGFR-1 and VEGFR-2.

TUBB3 confers chemoresistance to taxanes. Our experiment results of paclitaxel resistance in AGS cells are consistent with other reports suggesting that TUBB3 affects chemoresistance to taxanes in diverse cancer cells.26-29 Raspaglio, et al.21 also reported that TUBB3 is not only a parameter related to the chemoresponsiveness, but also could be a pure prognostic marker. TUBB3 expression levels differ by cell and tissue types. In some tissues, TUBB3 is constitutively expressed and is not inducible upon hypoxia.21 In AGS cells, we observed TUBB3 was constitutively expressed in normoxia and became more induced in hypoxia.

The present study demonstrated that blockade of both VEGFR-1 and VEGFR-2 in conjunction with paclitaxel synergistically depresses induction of HIF-1α and TUBB3 expression, and more effectively increases cytotoxicity in gastric cancer cells.

**Fig. 5.** Blockade of VEGFR-1 and VEGFR-2 decreases resistance to paclitaxel in AGS cells. The cell viability assay demonstrated that AGS cell cytotoxicity was increased following combined treatment with paclitaxel and bevacizumab compared with treatment with paclitaxel alone. The increase of cytotoxicity was most pronounced when paclitaxel, anti-VEGFR-1, and anti-VEGFR-2 were applied simultaneously. Cells were maintained in normoxia or hypoxia for 24 h with paclitaxel following a 4-h pre-incubation with neutralizing antibody. Cell proliferation was normalized on the normoxic control. Values are expressed as means±SEM (n=3). *p<0.05. 

VEGFR, vascular endothelial growth factor receptor; SEM, standard error of the mean.

activation, and metastasis. Treatment with VEGFR-1 inhibitors, such as anti-VEGFR-1 antibody, suppresses tumor growth and metastasis in various models.26 However, the degree of tumor growth inhibition varies. Some studies have reported that VEGFR-1 inhibition is not sufficient to block tumor growth without combined inhibition of VEGFR-2.26,29 In addition, it is unclear if VEGFR-1 inhibitors, by preventing the binding of VEGF to VEGFR-1, increase the concentration of free VEGF that can subsequently activate VEGFR-2 and stimulate angiogenesis by an alternate pathway. The precise mechanisms of VEGFR-1 inhibitor functioning warrant further exploration.26

We demonstrated that HIF-1α expressions increase in association with elevated PGF. HIF-1α and TUBB3 were up-regulated in hypoxia and became more induced in response to PGF treatment. We also demonstrated that inhibition of VEGFR-1 is associated with decreases in HIF-1α and TUBB3 expression. Calvani, et al.18 reported that VEGFR-2, rather than VEGFR-1, mediates VEGF-dependent induction of HIF-1α in hypoxic HCT116 colon cancer cells, suggesting that functional VEGFR-2, but not functional VEGFR-1, exists in this colon cancer cell line. Cell viability assay results demonstrated that AGS cell cytotoxicity was most pronounced when cells were treated simultaneously with paclitaxel, anti-VEGFR-1, and anti-VEGFR-2. These results confirm that the dual inhibition of VEGFR-1 and VEGFR-2 with bevacizumab enhances paclitaxel sensitivity in AGS cells.

**ACKNOWLEDGEMENTS**

This study was supported by a grant (CRI111073-1) Chonnam national university hospital research institute of clinical medicine.

**REFERENCES**

1. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14 Suppl 2:i31-6.

2. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, et al. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 2009;41:122-31.

3. Hruban RH, Yardley JH, Donehower RC, Boitnott JK. Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 1989;63:1944-50.

4. Ajani JA, Fodor MB, Tjulandin SA, Moiseenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660-7.

5. Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer 2002;5:142-7.

6. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999;85:295-301.
10. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric cancer. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2006;11:301-6.

11. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.

12. Banerjee A. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun 2002;293:598-601.

13. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997;100:1282-93.

14. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999;80:1020-5.

15. Ranganathan S, Benetatos CA, Colarussio PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998;77:562-6.

16. Urano N, Fujiwara Y, Doki Y, Kim SJ, Miyoshi Y, Noguchi S, et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006;28:375-81.

17. Otrock ZK, Hatoum HA, Awada AH, Ishak RS, Shamseddine AI. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol 2009;70:93-102.

18. Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 2008;68:285-91.

19. Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E, et al. Expression of hypoxia-inducible factor-Ialpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003;105:176-81.

20. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.

21. Raspaglio G, Filippetti F, Priselli S, Penci R, De Maria I, Cicchilitti L, et al. Hypoxia induces class III beta-tubulin gene expression by HIF-Ialpha binding to its 3' flanking region. Gene 2008;409:100-8.

22. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.

23. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.

24. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.

25. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76.

26. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8:942-56.

27. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80.

28. Gille J, Heidenreich R, Pinter A, Schmitz J, Boehme B, Hicklin DJ, et al. Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int J Cancer 2007;120:1899-908.

29. Lyden D, Hattori K, Dias S, Costa C, Blakie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-201.